CN1947715A - Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis - Google Patents
Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis Download PDFInfo
- Publication number
- CN1947715A CN1947715A CN 200610030915 CN200610030915A CN1947715A CN 1947715 A CN1947715 A CN 1947715A CN 200610030915 CN200610030915 CN 200610030915 CN 200610030915 A CN200610030915 A CN 200610030915A CN 1947715 A CN1947715 A CN 1947715A
- Authority
- CN
- China
- Prior art keywords
- columbin
- fibleucin
- group
- different
- gulunbin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of Gulunbin and/or iso-Gulunbin and/or deoxyfibraurin in preparing the medicines in the form of tablet, coated tablet, capsule, suppository, nasal aerosol, paster, or injection for treating rheumatic and rheumatoid arthritis is disclosed.
Description
Technical field
The invention belongs to medical technical field, be specifically related to the new medical use of Columbin, different Columbin, Fibleucin, relate in particular to Columbin, different Columbin, the application of Fibleucin in preparing prevention and treatment rheumatism, medicine for treating rheumatoid arthritis.
Background technology
Rheumatism is a worldwide disease, can occur among different ages, sex, race, weather geographical environment and the social crowd.Approximately per 7 people just have 1 rheumatic patient in the world, and almost everyone is in the symptom that certain period occurs a rheumatism in all one's life.The symptom of rheumatism is varied, and delay can continue several days or the several years repeatedly, can have no adverse effects, and also can cause handicap.Rheumatoid arthritis is a kind of autoimmune disease, is that to damage with chronic progressive external synovium of joint and articular cartilage be the diseases associated with inflammation of feature, almost influences 1% of world population.Rheumatic arthritis is a kind of multiple commonly encountered diseases, and its morbidity is closely related with the various kinds of cell function and the imbalance of excretory cytokine thereof of body immune system.The preferred plan of treatment autoimmune disease is to help the due autoimmune tolerance status of body recovery, but the method for artificial induction's immunologic tolerance is still immature at present, and this target is still difficult to be realized.The Therapeutic Method of rheumatism has multiple, and wherein Drug therapy occupies an important position.But the medicament categories for the treatment of rheumatism at present is few, more lacks specific medicament.And the adverse effect of treatment rheumatism is more.Increasing clinical data shows that Chinese medicine rheumatic, rheumatoid arthritis have good efficacy.
In recent years, the antiinflammatory immunity function of Chinese medicine oneself be subjected to paying close attention to widely.The effect that a lot of Chinese medicines of clinical and experiment confirm have the moist disease of wind resistance has played the mitigate the disease effect by pain relieving, blood circulation promoting and blood stasis dispelling to rheumatism, but can not reach the effect that changes the course of disease, and also has certain toxicity.China's Chinese medicine and pharmacy has a long history, and traditional Chinese medical science scholar's utilization is treated the trend of rheumatic, rheumatoid arthritis in continuous rising through proved recipe.In these in the medical herbs effective ingredient, infer the active substance that very likely has the treatment rheumatism, so, the lead compound that screening has a moist disease activity of wind resistance from the natural product desirable approach of can yet be regarded as; And then the structural modification by carrying out lead compound and complete synthesis, the active stronger monomer of screening from a series of derivative compounds again, and in conjunction with the structure activity study of the moist disease activity of wind resistance, the final medicine found with potential applicability in clinical practice.
Radix Tinosporae is the dried root of Menispermaceae Tinospora plant limacia sagittata (Tinospora sagittata (Oliv.) Gagnep.) or Radix Tinosporae (Tinospora capillipes Gagnep.), has another name called nine Fel Bovis seu Bubali, gold silver bag (Guangxi), Herba Elephantopi scaberis (Sichuan), nine Fructus Arctii (Jiangxi), potato (Hunan).Go through version by Chinese Pharmacopoeia and recorded, the effect of heat-clearing and toxic substances removing, relieving sore throat and pain is arranged.Be used for laryngopharynx swelling and pain, the carbuncle furunculosis is had loose bowels, dysentery, gastral cavity abdomen burning pain.(Chinese Pharmacopoeia (a .2005 version): 150-151. Beijing: Chemical Industry Press).
The Radix Tinosporae capsule is through clinical verification 270 examples, upper respiratory tract infection 76 examples wherein, and acute tonsillitis's 10 examples, pharyngolaryngitis 78 examples, acute gastroenteritis 24 examples, pneumonia 40 examples, tracheitis 42 examples are cured 136 examples, account for 50.4%; Effective 120 examples account for 44.4%; Invalid 14 examples account for 5.25%; Total effective rate is 94.8%.Radix Tinosporae ethanol soaks beyond the region of objective existence applying treatment transfusion induced phlebitis 78 examples, cures 64 examples, accounts for 82.2%; 12 examples that take a turn for the better account for 15.2%; Invalid 2 examples.Account for 2.6%; Total effective rate is 97.4%.Compare with matched group magnesium sulfate, cure rate and effective percentage are learned processing by statistics all significant difference (P＜0.01, P＜0.05).
Though Radix Tinosporae has so good clinical application effect, because to its chemical constitution study not deeply, the pharmacological screening deficiency causes active component indeterminate.We identify by chemical constituent separation, purification, the structure of the Radix Tinosporae medical material being carried out system, find mainly to contain a large amount of diterpenoid-lactones and Protoberberine Alkoloids in the Radix Tinosporae, further the pharmacologically active screening proves, being mainly Columbin (columbin), different Columbin (isocolumbin), Fibleucin (fibleucin) in the diterpenoid-lactone, is the active component of the moist disease of its wind resistance.
Summary of the invention
The objective of the invention is to propose Columbin, different Columbin, Fibleucin are used for preventing and treating rheumatic, medicine for treating rheumatoid arthritis in manufacturing application.
The structural formula of the said Columbin of the present invention, different Columbin, Fibleucin is:
The different Columbin structural formula of Columbin structural formula Fibleucin structural formula
Columbin, different Columbin, Fibleucin that the present invention proposes can extract from Radix Tinosporae medical material or other plant, obtain through separation and purification, also can be that the method through chemosynthesis prepares.
Experimentation proves, the effect that the combination of one or more of Columbin, different Columbin, Fibleucin has the moist disease of tangible wind resistance.
Columbin, different Columbin, Fibleucin is a kind of or be combined as active component to kind, add one or more pharmaceutically the acceptable carrier can be prepared into the pharmaceutical composition that is used for clinical treatment, be used for the treatment of human righteousness's deficiency, the wet dry limbs joint myalgia that waits the exopathogen invasion and attack to cause of wind and cold, weighing, numb, swelling, joint stuffiness, very then joint deformity, or involve the class disease that internal organs are feature, or to be used for the treatment of with the joint synovitis disease be the chronic general autoimmunity connective tissue disease disease of feature, comprises treatment rheumatic and rheumatoid arthritis.
Pharmaceutically acceptable carrier mentioned above is meant the pharmaceutical carrier of pharmaceutical field routine, for example: diluent, excipient such as water etc.; Filler such as starch, sucrose etc.; Binding agent such as cellulose derivative, alginate, gelatin and polyvinylpyrrolidone; Wetting agent such as glycerol; Disintegrating agent such as agar, calcium carbonate and sodium bicarbonate: absorption enhancer such as quaternary ammonium compound; Surfactant such as hexadecanol; Absorption carrier such as Kaolin and soap clay; Lubricant such as Pulvis Talci, calcium stearate and magnesium and Polyethylene Glycol etc.Can also in compositions, add other adjuvant such as flavouring agent, sweeting agent etc. in addition.In the described medicine, the weight content of above-mentioned active component is 1-99%.
The preparation of Columbin, different Columbin, Fibleucin can be by oral, percutaneous, and snuffing is gone into, the mode of rectum, parenteral, vein or muscle administration is applied to the patient who needs this treatment.Be used for when oral, can be made into conventional solid preparation such as tablet, powder, pill, capsule etc., or make liquid preparation such as water or oil-suspending agent, or other liquid preparation such as syrup, elixir etc.; When being used for parenteral, can be made into solution, water or the oiliness suspending agent etc. of injection.Preferred form is tablet, coated tablet, capsule, suppository, nasal spray, patch and injection.
The following examples can make those skilled in the art more fully understand the present invention, but do not limit the present invention in any way.
The specific embodiment
Embodiment 1:
The dry medical material 2.5kg of Radix Tinosporae, with 50 liters of reflux, extract, of 95% solution 2 times, each 2 hours, merge extracted twice liquid, concentrating under reduced pressure obtains extractum 120g, after the dispersion of 2 premium on currency, divides three extractions with the 6L chloroform; Concentrating under reduced pressure extraction position, obtain crude product 20g, with crude product with 500 ml methanol heating for dissolving, filtered while hot, filtrate is put 4 ℃ of refrigerator and cooled and is hidden and spend the night, separate out Columbin, different Columbin, the crystallization of Fibleucin compositions, filter paper filtering, drying obtains compositions 12g, get compositions 10g, mix with 50g silica gel and to mix sample, be added to the silicagel column top that has installed, with petroleum ether: chloroform (20: 1～5: 1) system's gradient elution, TLC follows the tracks of, merge and to contain the identical eluent of composition, be evaporated to driedly, obtain Columbin monomer 200mg, different Columbin 3.7g, Fibleucin 3.0g.
Embodiment 2:
Tablet: active component (three kinds monomer or compositions) 17g
Lactose 200g
Corn starch 50g
Magnesium stearate 3g
Make 1000
Preparation method: active component, lactose and starch are mixed, and water is the moistening soft material of making evenly, the granulating mixture after moistening, crosses 20 mesh sieves, 80 ℃ of oven dry add magnesium stearate, after sieve, with the mixture tabletting, every weighs 270mg then, and active component content is 17mg.
Embodiment 3:
Transfusion: active component 2g
Sodium chloride 9g
Water for injection 100000ml
Make 1000 bottles
Preparation method: active component and sodium chloride are dissolved in the water for injection of 100000ml, add 0.01% activated carbon adsorption, intermediate detects, the 0.45um membrane filtration, and packing, the 100ml/ bottle, sterilization, check is promptly.
Embodiment 4:
Columbin, different Columbin, Fibleucin are to the rat assist agent arthritis preventive and therapeutic effect.
1 laboratory animal
The SD rat, male and female dual-purpose, body weight 180-220g.
2. experimental model and method of testing
Get 80 of rats, be divided into 8 groups at random, with molten long-pending (ml) below the drainage mensuration normal condition bottom right joint, cause inflammation in the left back ankle intradermal injection of every Mus 0.1ml Freund's complete adjuvant then, respectively at causing scorching back 6,12,18,24,48h cause scorching foot with the method measurement volume, so that difference is represented its swelling degree before and after scorching, to observe the influence of medicine to the rat assist agent arthritis primary affection.And respectively at cause the 12nd, 15 after the inflammation, 19d measures the non-volume-variation that causes scorching foot (right foot) with method, to observe the influence of medicine to the swelling of rat assist agent arthritis rat secondary inflammation.Cause scorching preceding 3d by the dosage gastric infusion shown in the table 6, matched group waits the normal saline of capacity, and once a day, successive administration is to the previous day of the day of drawing materials.
Rat is put to death after causing scorching 19d, causes non-that the 0.5cm place wins swelling foot pawl above the scorching side ankle joint, vertically cuts, and puts into the test tube that has the 5ml normal saline, 4 ℃ of soaked overnight, and the centrifuging and taking supernatant ,-20 ℃ of preservations are to be measured.PGE
2Assay adopt and to put the method for exempting from, press the test kit description and operate.
3 statistical analysiss:
All experimental result is all represented with mean ± standard error.Check the relatively significant difference of data between two groups with student t-, P＜0.05, expression difference has the significance meaning.
4 result of the tests:
Table 1. Columbin, different Columbin, Fibleucin are to the influence (n=10) of rat assist agent arthritis constitutional inflammation
| Group | Dosage (mg/kg) | Rat constitutional foot swelling degree (ml) | ||||
| 6h | 12h | 18h | 24h | 48h | ||
| The different Columbin group of matched group ibuprofen group Columbin group | - 0.75 10 20 10 | 1.20±0.08 0.31±0.10 b 1.03±0.06 0.61±0.12 a 0.71±0.12 | 1.01±0.11 0.36±0.10 b 0.93±0.26 0.56±0.09 b 1.03±0.16 | 0.940.18 0.26±0.09 b 0.76±0.16 0.51±0.26 b 0.94±0.12 | 0.92±0.17 0.25±0.12 b 0.75±0.12 0.54±0.09 b 0.92±0.09 | 0.81±0.15 0.24±0.10 b 0.74±0.10 0.51±0.08 b 0.89±0.11 |
| The Fibleucin group | 20 10 20 | 0.47±0.10 b 0.82±0.13 0.31±0.10 b | 0.62±0.04 0.85±0.13 0.30±0.06 b | 0.56±019 b 0.79±0.14 0.28±0.19 b | 0.54±0.12 b 0.75±0.13 0.27±0.10 | 0.54±0.10 b 0.75±0.12 0.27±0.11 b |
A and blank compare, and p＜0.05. b and blank compare, p＜0.01.
The result shows, compares with matched group, and the Columbin high dose group, different Columbin high dose group, Fibleucin high dose group 6-48h after causing inflammation all has the effect of former foot swelling of remarkable inhibition rat assist agent arthritis.
Table 2. Columbin, different Columbin, Fibleucin are to the influence (n=10) of rat assist agent arthritis Secondary cases foot swelling
| Group | Dosage (mg/kg) | Rat Secondary cases foot swelling degree (ml) | ||
| 11d | 15d | 19d | ||
| Control group Fenbid group Columbin group isocolumbin group fibleucin group | - 0.75 10 20 10 20 10 20 | 0.90±0.18 0.38±0.10 b 0.89±0.06 0.56±0.12 a 0.97±0.13 0..36±0.13 b 0.46±0.17 b 0.31±0.10 b | 1.01±0.11 0.37±0.10 b 0.93±0.16 0.58±0.09 a 1.03±0.16 0.45±0.04 b 0.39±0.13 b 0.30±0.06 b | 0.94±0.18 0.24±0.09 b 0.96±0.18 0.60±0.06 a 0.94±0.12 0.54±019 b 0.30±0.14 b 0.28±0.19 b |
A and blank compare, and p＜0.05. b and blank compare, p＜0.01.
The result shows, for the arthritic foot swelling of rat assist agent arthritis Secondary cases, compares with matched group, and the Columbin high dose group, different Columbin high dose group, the high low dose group of Fibleucin is at 11d, and 15d, 19d all have remarkable inhibitory action.
Table 3. Columbin, different Columbin, Fibleucin are to PEG in the immersion of rat joint
2Influence (n=10)
| Group | Dosage (mg/kg) | PEG 2Content (ng/ml) |
| Control group Fenbid group Columbin group isocolumbin group fibleucin group | - 0.75 10 20 10 20 10 20 | 14.06±6.10 8.11±2.10 8.98±3.10 8.13±2.02 8.65±2.95 8.23±3.20 8.31±1.01 a 8.15±0.90 a |
A and blank compare, p＜0.05.
The result shows, for the non-PEG that causes in the scorching joints of foot liquid behind the treatment 19d
2Content Columbin high dose group, different Columbin high dose group, the high low dosage of Fibleucin all has remarkable downward modulation effect.
Embodiment 5:
Columbin, different Columbin, Fibleucin are to the inductive arthritic inhibitory action of II Collagen Type VI (CIA)
1 laboratory animal
The Wistar rat, 130-150g.
2. model copy and animal grouping
Select 10 as normal control at random from 130 rats, all the other are used for model copy.The method of reference literature is mixed with II Collagen Type VI Emulsion, and along rat back and 5 intradermal injections of root of the tail part, every some 0.05ml divides 2 Intradermal booster injections behind the 15d.The normal control group gives the 9.0g/L sodium chloride injection and injects with method.With reference to the arthritis index standards of grading model copy effect is assessed behind the initial immunity 30d, the rat (about 50%) that scoring reached more than 6 minutes is used to continue experiment.The rat of model copy success is divided into 7 groups at random, 10 every group, respectively as CIA model group and administration group.The dosage according to the form below also is mixed with injection with propylene glycol in advance.Medication in 3 days 1 time.
3 draw materials
Rat claims quality, and with 20ml/L pentobarbital sodium 2.5ml/kg intraperitoneal anesthesia, ventral aorta blood sampling, conventional separation of serum is used to detect cytokine; It is fixing that rat faces upward the position, opens knee joint cavity, with 9.0g/L sodium chloride injection 1ml flushing articular cavity, collects arthral fluid, is used to detect cytokine.
The detection of 4 cytokines
Operate according to the explanation that ELISA test kit company provides.
5 statistical methods
Carry out statistical analysis with SPSS 11.5 statistical softwares, group difference adopts the t check, and the result represents with the mean value variance.
6 result of the tests
Table 4 is respectively organized TNF alpha content in peripheral blood and the articular cavity
| Group | Dosage (mg/kg) | The TNF alpha content | |
| Peripheral blood | Arthral fluid | ||
| The different Columbin group of matched group model group Columbin group Fibleucin group | - 0.75 10 20 10 20 10 20 | 14.06±3.91 35.09±8.82 b 18.26±4.12 a 15.35±3.56 a 20.63±3.65 b 17.05±2.36 a 17.95±3.81 a 15.88±6.25 a | 19.42±4.23 44.17±8.94 b 25.15±3.18 a 22.54±4.76 a 28.32±6.13 b 26.65±5.36 a 24.65±4.82 a 23.85±4.31 a |
A and model group compare, and p＜0.01. b and blank compare, p＜0.05.
In the CIA model group, the TNF alpha content in peripheral blood and the articular cavity is the highest, and behind drug treatment, the TNF alpha levels obviously descends in rat peripheral blood and the articular cavity, shows that medicine can reduce TNF alpha levels (P＜0.01).
Table 5 is respectively organized IL-6 content in peripheral blood and the articular cavity
| Group | Dosage (mg/kg) | IL-6 | |
| Peripheral blood | Arthral fluid | ||
| The different Columbin group of matched group model group Columbin group Fibleucin group | - 0.75 10 20 10 20 10 20 | 23.69±3.63 76.58±6.81 b 42.45±5.72 a 38.95±4.52 a 44.25±6.89 a 35.21±3.69 a 45.23±3.98 a 38.23±5.41 a | 19.38±2.24 88.69±10.56 b 48.36±5.97 a 46.12±3.68 a 47.54±9.16 a 39.23±5.46 a 40.12±5.13 a 41.36±8.13 a |
A and model group compare, and p＜0.01. b and blank compare, p＜0.05.
In the CIA model group, the IL-6 content in peripheral blood and the articular cavity is the highest, and behind drug treatment, the IL-6 level obviously descends in rat peripheral blood and the articular cavity, shows that medicine can reduce IL-6 level (P＜0.01).
Table 6 is respectively organized IL-10 content in peripheral blood and the articular cavity
| Group | Dosage (mg/kg) | IL-10 | |
| Peripheral blood | Arthral fluid | ||
| The different Columbin group of matched group model group Columbin group Fibleucin group | - 0.75 10 20 10 20 10 20 | 23.47±2.68 17.53±2.07 b 21.23±2.91 a 23.23±1.98 a 22.56±2.13 a 23.95±1.23 a 20.85±2.65 a 22.87±2.45 a | 15.29±2.54 10.59±2.56 b 14.74±1.85 a 15.87±2.46 a 13.96±1.56 a 14.79±2.48 a 14.85±2.68 a 15.36±2.13 a |
A and model group compare, and p＜0.01. b and blank compare, p＜0.05.
In the CIA model group, the IL-10 content in peripheral blood and the articular cavity significantly reduces, and behind drug treatment, the IL-10 level obviously rises in rat peripheral blood and the articular cavity, shows that medicine can improve IL-10 level (P＜0.01).
Claims (3)
1, one or more the application of compositions in preparation treatment of arthritis medicine of Columbin, different Columbin, Fibleucin, described Columbin, different Columbin, Fibleucin are separation and purification obtains from plant the chemical compound or the chemical compound of chemosynthesis, and arthritis comprises rheumatic and rheumatoid arthritis.
2, a kind ofly be used for the treatment of arthritic pharmaceutical composition, it is characterized in that containing the Columbin for the treatment of effective dose, different Columbin, Fibleucin and pharmaceutically acceptable carrier.
3, pharmaceutical composition according to claim 2 is characterized in that its dosage form is an injection, tablet, pill, capsule, solution, suspending agent, Emulsion, nasal spray, patch a kind of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100309152A CN100522158C (en) | 2006-09-07 | 2006-09-07 | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100309152A CN100522158C (en) | 2006-09-07 | 2006-09-07 | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1947715A true CN1947715A (en) | 2007-04-18 |
| CN100522158C CN100522158C (en) | 2009-08-05 |
Family
ID=38017404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100309152A Expired - Fee Related CN100522158C (en) | 2006-09-07 | 2006-09-07 | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100522158C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603764A (en) * | 2011-01-25 | 2012-07-25 | 苏州宝泽堂医药科技有限公司 | Extraction method of columbin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1772250A (en) * | 2004-11-09 | 2006-05-17 | 马本立 | Haobai prepn for treating wetness impair and its prepn process |
-
2006
- 2006-09-07 CN CNB2006100309152A patent/CN100522158C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603764A (en) * | 2011-01-25 | 2012-07-25 | 苏州宝泽堂医药科技有限公司 | Extraction method of columbin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100522158C (en) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101161251B (en) | Teasel root total saponin as well as its extracting method and application | |
| CN1843399A (en) | Medicine for treating benign prostate hyperplasia and its preparation process | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN1286466C (en) | Chinese medicine preparation for treating rheumatism and preparation and use | |
| CN1686377A (en) | Chuankezhi (pant treating) powder injection and its preparation method | |
| CN106074810A (en) | A kind of three wonderful capsules and preparation method thereof | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN100522158C (en) | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis | |
| CN100502859C (en) | Use of columbin, isocolumbin, deoxidized fibraurin in preparing antiphlogistic medicine | |
| CN101040891A (en) | Method of preparing tripterygium hypoglaucum (Levl) hutch alkaloids | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN1989990A (en) | Medicine for treating erection dysfunction and preparation method thereof | |
| CN100337644C (en) | Chinese medicine for treating peptic ulcer and its prepn process | |
| CN104490965B (en) | The application of panax japonicus polysaccharides, panax japonicus total saponins and panax japonicus saponin V | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1426783A (en) | Application of evodiamine in the preparation of medicine | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN101474315B (en) | Effective component group of stem-bark or root-bark of Daphne giraldii as well as preparation method and use thereof | |
| CN1899439A (en) | Chinese medicine composition for treating goat and its use | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN1989995A (en) | Medicine for treating benign prostate hyperplasia and its preparation process | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1785410A (en) | Preparation method of ready prepared chinese medicinal granules for treathing pains |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090805 Termination date: 20120907 |